Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Receivables: 2020-2024

Historic Receivables for Whitehawk Therapeutics (WHWK) over the last 4 years, with Dec 2024 value amounting to $5.9 million.

  • Whitehawk Therapeutics' Receivables rose 7.56% to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.3 million, marking a year-over-year increase of 13.94%. This contributed to the annual value of $5.9 million for FY2024, which is 7.56% up from last year.
  • According to the latest figures from FY2024, Whitehawk Therapeutics' Receivables is $5.9 million, which was up 7.56% from $5.5 million recorded in FY2023.
  • Whitehawk Therapeutics' 5-year Receivables high stood at $14.1 million for FY2020, and its period low was $1.9 million during FY2022.
  • Its 3-year average for Receivables is $4.4 million, with a median of $5.5 million in 2023.
  • Data for Whitehawk Therapeutics' Receivables shows a peak YoY surged of 194.74% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Whitehawk Therapeutics' Receivables stood at $14.1 million in 2020, then reached $1.9 million in 2022, then soared by 194.74% to $5.5 million in 2023, then climbed by 7.56% to $5.9 million in 2024.